Categories: All postsAnalysts

Calian Group gets price target raise at Echelon Wealth Partners

A quarter that beat street expectations across the board has Echelon Wealth Partners analyst Ralph Garcea raising his price target on Calian Group (Calian Group Stock Quote, Chart, News: TSX:CGY).

On Wednesday, Calian Group reported its Q1, 2018 results. The company earned $4.07-million on revenue of $75.8-million, a topline that was up 10.3 per cent over the same period last year.

“The results for this quarter continue to show the benefit of the combined strength of our five service offerings,” CFO Jacqueline Gauthier said. “The increase in revenues this quarter from both organic and acquisitive means allowed the company to report record quarterly revenues. In addition, with significant improvement in gross margin percentages, the company was able to increase its EBITDA levels at a higher pace than its revenue growth, while at the same time continue investments in its business development and delivery capabilities, therefore providing for a solid return to shareholders.”

Garcea summarized the quarter, explaining his second target raise in just a few months.

“CGY reported revenue of $75.7M (EWP: $74.2M; Cons: $72.9M) (+10% y/y), EBITDA of $6.4M (EWP: $5.6M; Cons: $5.8M), and EPS of $0.52 (EWP: $0.47; Cons: $0.48). Gross margin came in at 19.4% versus our 19.0% estimate. The mix of revenues in the quarter helped the margin beat on gross margin and EBITDA, especially in BTS where EBIT margins were a record 7.1%. CFOPS excluding working capital was $6.7M (EWP: $5.2M) with FCF of ($8.3M) due to a working capital build of $12.6M. Book-to-bill of -0.1 is not an accurate reflection due to the distorted nature of FQ417 when the Company signed $932M worth of contracts. Backlog as at quarter end was $1,181M, down from $1,261M q/q. CGY upped its credit facility two quarters ago from $10M to $40M to facilitate organic and inorganic growth with comfort levering up to 2x EBITDA. F2018 guidance was reiterated with revenue expected between $290-310M and EPS between $1.90-2.20. Continued execution by prudent management give us confidence in margin profiles going forward and further justifies our recent upgrade in November 2017.

In a research update to clients today, Garcea maintained his “Buy” rating, but raised his one-year price target on Calian Group from $40.00 to $41.00, implying a return of 33.3 per cent at the time of publication.

Garcea thinks Calian Group will generate EBITDA of $25.0-million on revenue of $301.0-million in fiscal 2018. He expects those numbers will improve to EBITDA of $27.0-million on a topline of $314.0-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cgy
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago